LOG IN
SIGN UP
MARKET
CARA
CARA
Cara Therapeutic
NASDAQ
Real-time Quotes | Nasdaq Last Sale
8.60
-0.53
-5.81%
Opening 14:57 07/01 EDT
OPEN
9.02
PREV CLOSE
9.13
HIGH
9.28
LOW
8.26
VOLUME
391.87K
TURNOVER
2.12M
52 WEEK HIGH
18.93
52 WEEK LOW
7.40
MARKET CAP
460.88M
P/E (TTM)
-4.8168
1D
5D
1M
3M
1Y
5Y
Marijuana Stock Movers For June 30, 2022
GAINERS: Marrone Bio Innovations (NASDAQ:MBII) shares closed up 6.42% at $1.16
Benzinga · 21h ago
Cara Therapeutics' Difelikefalin Aces Mid-Stage Study In Patients With Itchy Skin Disorder
Benzinga · 1d ago
Cara reaches main goal in mid-stage trial for pruritus therapy in nerve disorder
Commercial-stage biopharma, Cara Therapeutics (NASDAQ:CARA</span...
Seekingalpha · 1d ago
BRIEF-Cara Therapeutics Announces Topline Results From Phase 2 Trial Of Notalgia Paresthetica Treatment
BRIEF-Cara Therapeutics Announces Topline Results From Phase 2 Trial Of Notalgia Paresthetica Treatment
Reuters · 1d ago
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieved on the WI-NRS ≥4-point responder analy...
GlobeNewswire · 1d ago
Cara Therapeutics' Pruritus Therapy Meets Primary Endpoint in Phase 2 Trial
MT Newswires · 1d ago
Cannabis Stock Gainers And Losers From June 27, 2022
GAINERS: MGC Pharmaceuticals (OTC:MGCLF) shares closed up 46.08% at $0.02
Benzinga · 3d ago
Cannabis Stock Gainers And Losers From June 22, 2022
GAINERS: 22nd Century Group (NASDAQ:XXII) shares closed up 20.25% at $1.96
Benzinga · 06/22 20:34
No Data
Learn about the latest financial forecast of CARA. Analyze the recent business situations of Cara Therapeutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 8 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
37.50%Strong Buy
50.00%Buy
12.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CARA stock price target is 25.00 with a high estimate of 30.00 and a low estimate of 13.00.
Current 8.56
EPS
Actual
Estimate
-0.50-0.38-0.25-0.13
Institutional Holdings
Institutions: 248
Institutional Holdings: 32.80M
% Owned: 61.20%
Shares Outstanding: 53.59M
TypeInstitutionsShares
Increased
47
2.78M
New
27
610.08K
Decreased
69
1.64M
Sold Out
26
303.37K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.54%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
President/Chief Executive Officer/Director
Christopher Posner
Chief Financial Officer
Richard Makara
Senior Vice President/Chief Scientific Officer
Frederique Menzaghi
Chief Compliance Officer/General Counsel/Secretary
Scott Terrillion
Other
Joana Goncalves
Lead Director/Independent Director
Martin Vogelbaum
Independent Director
Harrison Bains
Independent Director
Jeffrey Ives
Independent Director
Susan Shiff
No Data
No Data
About CARA
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.
Webull offers kinds of Cara Therapeutics Inc stock information, including NASDAQ:CARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARA stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading CARA stock methods without spending real money on the virtual paper trading platform.